As we continue to celebrate our recent acquisition of ReceptoPharm, I would like to take a moment and welcome Dr. Paul Reid and Mr. Harold Rumph to the Nutra Pharma Board of Directors. For the past several years, I have had the pleasure of working closely with both Dr. Reid and Mr. Rumph at ReceptoPharm. [...]

Read Full Post »

Just over a month ago, we completed an exciting and important acquisition of the remaining equity in our drug discovery holding, ReceptoPharm.  Even though it has taken more than a year and a half since we first signed a letter of intent to acquire them, we are just as excited today as we were in [...]

Read Full Post »

After talking to a number of shareholders, it has become apparent that many of you haven’t seen our video from Business & Beyond. This short six-minute presentation offers a great overview about us and our drug discovery and medical devices subsidiaries, ReceptoPharm and Designer Diagnostics. In the future, we are going to be posting our [...]

Read Full Post »

According to The Deal’s recent interview with Dr. Matt Higgins, Management Professor at Georgia Institute of Technology, big pharma’s need to acquire new technology is increasing. He explains that expanded competition from generics and internal productivity issues with research not pumping out as many new drugs are to blame. What could potentially be viewed as [...]

Read Full Post »

World TB Day is less than a week away on March 24th, so I though this would be a good opportunity to discuss the current state of Tuberculosis and what Nutra Pharma is doing to help those affected by it. Before I began at Nutra Pharma in 2002, I thought Tuberculosis was a disease of [...]

Read Full Post »